<DOC>
	<DOCNO>NCT00413283</DOCNO>
	<brief_summary>The purpose study identify effective , well tolerate dose schedule romiplostim appropriate treatment chemotherapy induce thrombocytopenia ( CIT ) patient non-small cell lung cancer receive gemcitabine platinum .</brief_summary>
	<brief_title>Dose/ Schedule Finding Trial Romiplostim Chemotherapy-Induced Thrombocytopenia ( CIT ) Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically cytologically confirm locally advanced metastatic stage IIIB stage IV NSCLC receive 21day cycle gemcitabine/carboplatin gemcitabine/cisplatin Life expectancy ≥ 12 week time screen Thrombocytopenia evidence platelet count ≤ 50 x 10^9/L qualify cycle chemotherapy , OR platelet count &lt; 100 x 10^9/L Day 22 qualify cycle ( eligibility inclusion : ability receive dose chemotherapy study ) , criteria ensure patient must dose delayed platelet recovery Ability receive dose schedule chemotherapy first onstudy treatment cycle give qualify cycle ( except Day 8 gemcitabine ) Absolute neutrophil count ( ANC ) ≥ 1,000/µL , hemoglobin ≥ 9.5 g/dL , platelet count ≥ 100 x 10 ^9/L Day 1 first study chemotherapy treatment cycle Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 time screen Adequate Liver function ; aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 3.0 x upper limit normal ( ULN ) ( except patient confirm diagnosis Gilbert 's Syndrome ) Adequate renal function ; serum creatinine &lt; 1.5 x ULN Receipt &gt; 1 prior systemic chemotherapy regimen Sepsis , disseminate coagulation condition ( i.e . immune [ idiopathic ] thrombocytopenic purpura [ ITP ] , thrombotic thrombocytopenic purpura [ TTP ] , hemolytic uremic syndrome [ HUS ] ) may exacerbate thrombocytopenia History unstable angina , congestive heart failure , uncontrolled hypertension ( diastolic &gt; 100 mmHg ) , uncontrolled cardiac arrhythmia , recent ( within 1 year screening ) myocardial infarction History arterial thrombosis ( e.g. , stroke transient ischemic attack ) within 1 year screen History pulmonary embolism venous thrombosis within 1 year screening ( except catheterrelated clot ) Use nitrosourea mitomycinC within 6 week screen Have receive thrombopoietic growth factor relate substance Have receive granulocyte macrophage colony stimulate factor ( GMCSF ) within last 4 week prior screen Have receive experimental therapy within 4 week prior screen Have ever receive bone marrow peripheral blood stem cell infusion ( within 1 year screening ) Known hypersensitivity recombinant E. coliderived product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Advanced Non-Small Cell Lung Cancer</keyword>
	<keyword>Chemotherapy Induced Thrombocytopenia</keyword>
	<keyword>CIT</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Stage IIIB NSCLC</keyword>
	<keyword>Stage IV NSCLC</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Cisplatin</keyword>
</DOC>